Olopatadine HCL 0.1% Ophthalmic Solution

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D222R0117

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Ontario, Canada, CANADA

SourceSAM
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Olopatadine HCL 0.1% Ophthalmic Solution in 5ML bottles. This contract, identified by procurement number SPE2D222R0117, is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505, indicating its focus on pharmaceutical products. The place of performance for this contract is Ontario, Canada. The primary objective of this procurement is to ensure a reliable supply of Olopatadine HCL 0.1% ophthalmic solution, a medication commonly used for the treatment of allergic conjunctivitis, to meet the ongoing needs of the Department of Defense. The contract encompasses the manufacturing and delivery of the specified pharmaceutical product, with a focus on quality, regulatory compliance, and supply chain security. Throughout the contract lifecycle, several key modifications have been implemented to address evolving requirements and regulatory standards. Notable modifications include: - Incorporation of clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1), reflecting the agency’s commitment to diversity, equity, and inclusion. - Updates to the manufacturer, place of performance, and National Drug Code (NDC) for the product, ensuring accurate sourcing and traceability. - Changes to the point of contact for Golden State Medical Supply, Inc. (CAGE code 1HT23), facilitating effective communication and contract management. - Exercise of option years to extend the contract’s period of performance, with Option Year 1 effective from February 15, 2024, through February 14, 2025; Option Year 2 from February 15, 2025, through February 14, 2026; and Option Year 3 from February 15, 2026, through February 14, 2027. - Incorporation of critical regulatory clauses, such as FAR 52.204-30 (Federal Acquisition Supply Chain Security Act Orders), Drug Supply Chain Security Act language, and FAR 52.204-27 (Prohibition on a ByteDance Covered Application), ensuring compliance with federal supply chain and cybersecurity requirements. - Adjustments to pricing and shipping dates to align with operational needs. The contract is managed by DLA Troop Support, a federal office responsible for providing logistical support to the Department of Defense. The primary and secondary points of contact for this procurement are Kyle Lewicki ([email protected], 445-737-0977) and Jason Wray ([email protected], 445-737-6304), respectively. This procurement is an active, ongoing contract, as indicated by its current status. Contractors interested in similar opportunities should note the emphasis on regulatory compliance, supply chain security, and adherence to federal acquisition requirements. The contract’s scope and deliverables are expected to remain consistent throughout its lifecycle, focusing on the timely and compliant delivery of Olopatadine HCL 0.1% ophthalmic solution to support the health and readiness of Department of Defense personnel. For further details and access to related documents, interested parties can refer to the official notice on SAM.gov using Opportunity ID df6c2375129a40959545546683d370c4.
Documents13